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Abstract
Background: It has been suggested that the HLA-G molecule is a genetic risk factor for Behcet's disease (BD). In this 
study, we evaluated the level of Qa-2, a murine nonclassical class I MHC molecule and possible functional homolog of 
HLA-G, to determine if it was associated with various symptoms of BD-like mice. In addition, we investigated siRNA 
(small interfering RNA) treatment to determine if it inhibited Qa-2 expression, thereby changing the symptoms of mice.
Methods: RNA interference (RNAi) and vector transfection were employed to manipulate gene expression in vivo in 
mice. siRNA (small interfering RNA) or Qa-2 expression vector was applied to inhibit or up-regulate Qa-2 expression, 
respectively.
Results: The Qa-2 levels in granulocytes were lower in BD-like mice than in normal controls. The silencing of Qa-2 by 
intravenous injection of siRNA (500 nmol/mouse, 4 times at 3-day intervals) specifically reduced the Qa-2 levels and 
worsened the BD-like symptoms.
Conclusions: Silencing Qa-2 by injecting siRNA into mice resulted in deterioration of symptoms in BD-like mice.
Background
Since HLA-G (human leukocyte antigen-G) was first
detected by Geraghty et al. [1], it has been reported that
HLA-G protein is expressed at the feto-maternal inter-
face during pregnancy [2] and on a subset of thymic epi-
thelial cells [3], and that it is also involved in maintenance
of tolerance of the maternal immune system toward the
semi-allogeneic fetus. HLA-G is also expressed in other
tissues such as intestinal mucosa [4] and PBMC [5].
Numerous studies have evaluated the relevance of HLA-
G under pathologic conditions such as transplantation,
autoimmunity, cancer, and hematologic malignancies [6].
HLA-G interacts with different natural killer (NK) cell
receptors and is able to inhibit NK and T-cell cytotoxicity,
as well as T-cell proliferation [7]. Interestingly, HLA-G
has been described as a unique ligand of the killer cell
inhibitory receptor, KIR2DL4, which is expressed on the
surface of all NK cells [8]. Furthermore, HLA-G inhibits
the transendothelial migration of NK cells [9], shifts the
cytokine balance toward Th2 dominance [10], and sup-
presses the proliferation of allogeneic CD4+ T lympho-
cytes [11,12]. Taken together, HLA-G exerts specific
inhibitory effects against immune cells. In addition,
recent studies indicate unexpected expression of HLA-G
proteins in chronic cutaneous inflammatory diseases,
such as psoriasis [13] and atopic dermatitis [14].
Behcet's disease (BD) is a chronic multi-systemic disor-
der that involves the gastrointestinal, mucocutaneous,
ocular, vascular, central nervous, and articular systems.
BD has a chronic course that includes periodic exacerba-
tions and progressive deterioration [15]. Although the
etiology of BD is unclear , viral infection has long been
postulated as one of its main factors. The viral hypothesis
has been verified by detection of the virus in saliva [16],
intestinal ulcers [17], and genital ulcers [18] of patients
with BD since it was first proposed by Hulûsi Behçet [19].
Furthermore, inoculation of the earlobe of ICR mice with
herpes simplex virus (HSV) enables development of a
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BD-like animal model [20]. Manifestations in mice fol-
lowing HSV inoculation involve multiple symptoms such
as oral ulcers, genital ulcers, skin ulcers, eye symptoms,
gastrointestinal ulcers, arthritis, and neural involvement,
as well as skin crusting. The frequency of these symptoms
is similar to that of patients with BD [21]. In addition to
viral causes of BD, several studies have identified lympho-
cyte dysfunction as a possible cause [22,23]. Thus, atten-
tion has been focused on the T helper (Th) 1 and Th2
cytokines, with Th1 cells perhaps playing a more impor-
tant role in the immunopathogenesis of BD [24]. When
the Th2 adjuvant, aluminium hydroxide (alum), was
mixed with ovalbumin (OVA) and injected into mice suf-
fering from BD, their cutaneous symptoms were
improved [25].
Park et al. [26] reported that the frequency of haplo-
types containing a HLA-G 3741_3754 14 base pair inser-
tion and 1597*delC was increased in BD patients.
Moreover, individuals who were homozygous with the
3741_3754*ins14/*ins14 genotype were found to have a
risk of BD that was 2.7-times greater than that of the con-
trols. The HLA-G 3741*+14bp induces a significantly
lower expression level than the complete HLA-G mRNA
isoforms. In addition, the HLA-G 3741_3754  14-base
pair insertion allele was found to occur significantly more
frequently in BD patients with ocular, arthritis, and CNS
symptoms than in controls, and this insertion was found
to be related to the lower serum level of HLA-G [26]. The
authors who presented these findings suggested that
these HLA-G allelic variants are genetic risk factors for
BD. In addition, the HLA-G*010101 alleles have been
shown to have a significantly lower frequency in BD
patients than in control subjects [27].
As a result, it is important to determine if HLA-G con-
tributes to the pathogenesis of BD. To accomplish this,
Qa-2 expression, the functional homolog of HLA-G in
mice, was identified and modulated by small interfering
RNA (siRNA) and the Qa-2 expression vector. The results
of this study confirmed that decreased Qa-2 levels are
related to changes in the disease pattern and deteriora-
tion of BD-like symptoms.
Methods
Animals, induction of BD-like symptoms, and scoring of BD 
activity
Five-week-old ICR male mice were used in this study. To
induce a BD-like disease in mice, their earlobes were
scratched with a needle and then inoculated with 1.0 ×
106 plaque forming units/ml of HSV type 1 (F strain).
Virus inoculation was performed twice with a 10-day
interval, after which the mice were observed for 30
weeks. Mice were housed in conventional temperature-
and light-controlled rooms (20-22°C, 12 h light cycle
starting at 8:00 a.m.) and had free access to food and
water. During the experiment, the animals were observed
closely. Mice were handled in accordance with the proto-
cols approved by our institutional animal care committee.
Manifestations in mice after HSV inoculation involved
multiple symptoms including oral ulcers, genital ulcers,
skin ulcers, eye symptoms, intestinal ulcers, arthritis, and
neural involvement, as well as skin crusting. Oral, genital,
and other skin ulcers (including bulla and crust), and eye
symptoms were all classified as major symptoms, while
other symptoms were classified as minor symptoms [20].
Overall, 15% of the HSV-injected mice developed BD-like
symptoms. The disappearance of symptoms and decrease
in lesion size constituted an improvement, similar to in
human patients.
The animals were observed once a week after HSV
inoculation, at which time the severity of BD was deter-
mined according to the BD activity index, as outlined in
the Behcet's Disease Current Activity Form 2006 http://
www.behcet.ws/pdf/BehcetsDiseaseActivityForm.pdf.
The occurrence of the following symptoms in the mouse
model were selected for analysis: mouth ulceration, geni-
tal ulceration, erythema, skin pustules, skin ulceration,
joints-arthritis, diarrhea, red eye (right, left), reduced
vision (right, left), loss of balance, discoloration, and
swelling of the face. The score of each symptom was one,
and the total score before and after treatment was used to
determine the severity of BD. Mice exhibiting signifi-
cantly reduced symptoms were photographed to docu-
ment improvement after treatment.
Synthesis and in vitro test of siRNA
Qa-2 siRNA oligonucleotides with the following sense
and anti-sense sequences were designed and synthesized
by Dharmacon (Chicago, IL, USA). The Qa-2 protein was
encoded by four genes in the Q region, Q6, Q7, Q8 and
Q9. These genes have a typical class I MHC gene struc-
ture involving exon 1 (leader peptide), exon 2 (α1
domain), exon 3 (α2 domain), exon 4 (α3 domain), exon 5
(transmembrane domain), and exons 6, 7 and 8 (cytoplas-
mic domains). As shown in Table 1, we selected four
sequences located in each domain to synthesize siRNA.
To confirm the function of interference, the synthesized
siRNA was tested in vitro in peripheral blood mononu-
clear cells (PBMC). To accomplish this, PBMCs were iso-
lated from 5-6 week-old ICR mice and cultured at 1 × 105
cells/ml in DMEM medium with 1% antibiotics and 10%
FBS. siRNA (200 nM) was incubated with 3 μL of oligo-
fectamin (Gibco-Invitrogen, Rockville, MD) in 200 μL of
DMEM medium. After 24 h of treatment with siRNA, the
PBMCs were harvested and subjected to RT-PCR.
In vivo siRNA injection
For application to mice, 500 nM of siRNA in 200 μL of 5%
glucose, including transfection reagent jetPEI (Polyplus,Lee et al. Journal of Inflammation 2010, 7:31
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France, Illkirchcedex), was intravenously injected into
mice one to four times with a three day interval between
injections. Two-days after the last injection, mice were
photographed and the PBMCs were analyzed using a flu-
orescence-activated cell sorter (FACS). The control group
was injected with 200 μL of 5% glucose. Qa-2 leader pep-
tide domain siRNA did not down-regulate the Qa-2
mRNA level in in vitro PBMC cultures when compared to
other domains; therefore, the leader peptide domain
siRNA was injected as a control. For in vivo administra-
tion to mice, 1.5 μL of transfection reagent was mixed
with 5% glucose and siRNA. The Qa-2 siRNA was mixed
with α3 domain, transmembrane domain and cytoplas-
mic domain in equal amounts, after which it was admin-
istered to mice.
Flow cytometry
To analyze the Qa-2 expression, cells were harvested and
fixed with 4% formaldehyde in 1% fetal bovine serum
containing PBS for 20 min at room temperature, after
which they were incubated with FITC-conjugated anti-
Qa-2 antibody (eBioscience, San Diego, CA, USA).
Stained cells were analyzed in F ACS V antage using the
Cell Quest software (Becton Dickinson, Franklin Lakes,
NJ, USA) by collecting at least 10,000 gated lymphocytes
[7].
Reverse transcription PCR (RT-PCR)
Total RNA was isolated using TRIzol (Life Technologies,
Helgerman, CT) according to the manufacturer's recom-
mendations. Two μg of total RNA were used as a template
for cDNA synthesis, which was conducted using a Super-
Script III First-Strand Synthesis System for RT-PCR kit
(Invitrogen, Carlsbad, CA). The cDNA was amplified by
PCR using the following primers: Qa-2, Sense: 5' -
AGGTCTTAT GGTGCTGTCAC-3', Anti sense: 5'- TGT
GTAATTCTGCTCCTTCC -3'; β-actin, Sense: 5'-TG
GAATCCTGTGGCATCCATGAAAC -3', Antisense: 5'-
TAAAACGCAGCTCAGTAACAGTCCG-3'; IFNγ,
Sense: 5'-AGCGGCTGACTGAACTCAGATTGTAG
CTTGTACCTTTACTTCACTG-3', Antisense: 5'-GTC
ACAGTTTTCA GCTGTATAGGG-3'. Amplified PCR
products were visualized on 1.2% agarose gels.
Real Time PCR
For real-time SYBR Green RT-PCR, a 20-μl reaction con-
taining 10 μl of 2× Quantitect SYBR Green Master Mix
(Qiagen, Valencia, CA, USA) was employed. The master
mix was composed of hot start Taq polymerase, a 0.4 μL
mix of 2 reverse transcriptases, 0.5 μL (10 ng/μL) of tem-
plate and 0.8 μL of primers. An ABI 7900 HT thermal
cycler (Lab Centraal B.V., Haarlem, The Netherlands) was
used for all real-time RT-PCR assays. Reverse transcrip-
tion was conducted at 50°C for 30 min, followed by dena-
turation at 95°C for 15 min. DNA was amplified by
subjecting the samples to 40 cycles of 95°C (30 s), 55°C
(30 s), and 72°C (30 s). Real-time RT-PCR data were col-
lected for 15 sec at 75°C to avoid non-specific fluores-
cence due to the formation of primer dimers at low
template concentrations. For generation of standard
quantitation curves, the cycle threshold values were plot-
ted proportionally against the logarithm of the input copy
numbers. Negative controls were included in each run.
Qa-2 vector construction
Qa-2 cDNA was amplified from total RNA extracted
from ICR mice lymph nodes by reverse transcriptase -
polymerase chain reaction (RT-PCR) using the following
primers: sense 5'-CGGGATCCCGATGGCTCTAACAA
TGCTGC-3', antisense 5'-CGGAATTCCGCTTCGTGT-
GAAAGTATGGAG-3'. The sense primer included the
BamH1 restriction site and the antisense primer included
the EcoR1 restriction site. The cDNA was subsequently
digested with BamHI and EcoRI and then inserted into
eukaryotic expression vector pcDNA3.1 (Invitrogen,
Carlsbad, CA, USA). Verification of the recombinant
construct was performed by DNA sequencing. The
empty vector pcDNA3.1 was used as a control. All plas-
m i d s  w e r e  p u r i f i e d  b y  t w o  r o u n d s  o f  p a s s a g e  t h r o u g h
Endo-Free columns (Qiagen, Chatsworth, CA, USA), as
described elsewhere [28].
Qa-2 vector transfection to HeLa cells
HeLa cells were maintained in Dulbecco's modified Eagle
medium (DMEM) supplemented with 2 mM glutamine,
100 units/ml penicillin, 100 μg/ml streptomycin, and 5%
(v/v) dextran-charcoal-treated fetal bovine serum at 37°C
in 5% CO2. Cells were plated at 106 cells/10 cm dish the
day before transfection, after which they were transfected
using a lipofectimine kit (Invitrogen, Paisley, UK) accord-
Table 1: Qa-2 siRNA oligonucleotide sequences
Qa-2 domain siRNA oligonucleotides sequences
Leader peptide 
domain
5'-CAACACUCGCAAUAUU-3'(sense)
3'-GUUGUGAGCGACGUUAUAA-5'(antisense)
α3 domain 5'-AGGUCUUAUGGUGCUGUCAUU-3'(sense)
3'-UUUCCAGAAUACCACGACAGU-
5'(antisense)
Transmembrane 
domain
5'-UGUGAUGAAUAGGAGGUGAUU-3'(sense)
3'-UUACACUACUUAUCCUCCACU-
5'(antisense)
Cytoplasmic 
membrane domain
5'-UAGAGCUCUGAUAGAUCUCUU-3'(sense)
3'-UUAUCUCGAGACUAUCUAGAG-
5'(antisense)Lee et al. Journal of Inflammation 2010, 7:31
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ing to the manufacturer's instructions. The vector
pcDNA3.1 was transfected into HeLa cells as a control.
Administration of Qa-2 vector to mice
Normal and BD mice were intraperitoneally injected once
with 50 ng of pcDNA 3.1 or pcDNA 3.1 Qa-2 vector per
mouse, and their splenocytes or macrophages were iso-
lated three days later and analyzed by flow cytometry.
Vector mixed with transfection reagent jetPEI was
injected into mice and the frequency of Qa-2 protein
expression was analyzed by FACS.
Statistical analysis
All data are presented as the mean ± SE. Statistical differ-
ences between groups were determined using a Student's
t test and the Bonferroni correction. Statistical analysis
was conducted using MedCalc® version 9.3.0.0.
Results
Qa-2 mRNA and Qa-2 positive PBMCs were lower in BD 
symptomatic mice than in normal healthy mice
RT-PCR revealed that Qa-2 mRNA expression in periph-
eral blood mononuclear cells (PBMC) of mucocutaneous
Figure 1 Qa-2 expression in PBMC of BD. A. RT-PCR demonstrated that mRNA expression was lower in PBMC of BD skin than in BD normal mice. B. 
The frequency of Qa-2 in PBMC of normal healthy controls, BD asymptomatic (BD normal) mice, BD mucocutaneous symptomatic mice (BD skin), and 
BD mucocutaneous and ocular symptomatic mice (BD eye) as determined by FACS analysis. In lymphocytes, the Qa-2 levels in BD eye mice were sig-
nificantly lower than in normal healthy mice (p = 0.036). These levels were also lower than in BD skin mice, although this difference was not significant. 
In granulocytes, the Qa-2 levels in BD eye mice were significantly lower than in normal healthy mice (p = 0.016). The Qa-2 levels in BD eye mice were 
lower than in normal and BD skin mice, although this difference was not statistically significant. Qa-2 levels in BD skin were significantly lower than in 
normal controls (p = 0.024). C. The portion of Qa-2 positive cells in lymphocytes or granulocytes. The frequency of Qa-2 positive cells in the granulo-
cytes of BD skin and BD eye mice was lower than in normal controls and BD normal mice (BDN). The frequencies of Qa-2 positive cells in BD eye mice 
were significantly lower than those in normal controls (p = 0.001).Lee et al. Journal of Inflammation 2010, 7:31
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symptomatic BD mice was down-regulated when com-
pared to asymptomatic BD mice, despite HSV inocula-
tion (BD normal, BDN) (Figure 1A). Next, Qa-2 levels in
PBMCs obtained from normal healthy mice, BD asymp-
tomatic mice (BDN), BD skin symptomatic mice (BD
skin), and BD eye symptomatic mice (BD eye) were ana-
lyzed by flow cytometry. The symptoms of BD skin con-
sisted of typical mucocutaneous symptoms in mice
without ocular symptoms, while those of BD eye mice
consisted of ocular symptoms with mucocutaneous
symptoms. After FACS staining, lymphocytes and granu-
locytes were separated by gating. In lymphocytes, Qa-2
positive cells accounted for 94.78 ± 3.56% in normal
healthy mice, 92.56 ± 6.13% in BD normal mice, 91.73 ±
5.96% in BD skin, and 84.49 ± 11.95% in BD eye mice. BD
eye mice were found to have a statistically lower number
of Qa-2 positive cells than normal healthy mice (p =
0.036). In granulocytes, Qa-2 positive cells were 87.01 ±
7.97% in normal healthy mice, 82.29 ± 17.47% in BD nor-
mal mice, 67.9 ± 21.42% in BD skin mice, and 56.00 ±
30.49% in BD eye mice. BD skin and BD eye mice showed
significantly lower levels of Qa-2 positive cells than nor-
mal healthy mice (p = 0.024, p = 0.016 each) (Figure 1B).
The portion of Qa-2 positive cells in the granulocytes of
BD skin and BD eye mice was lower than that of normal
control and BD normal (BDN) mice. The portion of Qa-2
positive cells in the granulocytes of BD eye mice was sig-
nificantly lower than that of normal controls (p = 0.001)
(Figure 1C). As shown in Figure 1, the decreased level of
Qa-2 was related to the BD symptoms.
RNA interference of Qa-2 transcription in vitro; Qa-2 siRNA 
reduced Qa-2 mRNA levels in PBMCs of normal mice
PBMCs isolated from normal mice were transfected for
24 h with Qa-2 siRNA with different domains, after
which the expression of Qa-2 was determined by reverse
transcriptase-PCR. siRNA for the α3 domain, transmem-
brane domain, and cytoplasmic domain inhibited the Qa-
2 level; however, the leader peptide domain did not.
Mixed siRNA consisting of equal amounts each of these
four domains did not downregulate the Qa-2 mRNA
level. Flow cytometric analysis also showed a decreased
frequency of Qa-2 expression in the Qa-2 siRNA domain-
treated groups, except for the leader peptide domain (Fig-
ure 2).
Downregulation of Qa-2 by intravenous injection of siRNA 
into BD mice
Next, an siRNA mixture composed of the siRNA of the
α3 domain, transmembrane domain and the cytoplasmic
domain was injected into BD mice. Five to six individual
BD mice in each group were intravenously injected once
Figure 2 Qa-2 siRNA reduced Qa-2 mRNA and the frequency of Qa-2 positive cells in PBMC of normal mice. PBMC isolated from mice were 
transfected with Qa-2 siRNAs with different Qa-2 domains for 24 hrs, and the expression of Qa-2 was then determined by reverse transcriptase-PCR 
and FACS analysis. Lanes 4, 5 and 6 (α3 domain, transmembrane domain, and cytoplasmic domain, respectively) showed that siRNA effectively re-
duced the Qa-2 mRNA levels. Lane 3 (leader peptide) did not decrease the Qa-2 level. Lane 7 (a mixture of leader peptide, α3 domain, transmembrane 
domain, and cytoplasmic domain) also did not decrease the Qa-2 level. Lane 1, control (not treated); Lane 2, 5% glucose treated; Lane 3, leader peptide 
200 nmole; Lane 4, α3 domain 200 nmole; Lane 5, transmembrane domain 200 nmole; Lane 6, cytoplasmic domain 200 nmole; Lane 7, mixed 200 
nmole (leader peptide + α3 domain+ transmembrane domain + cytoplasmic domain).Lee et al. Journal of Inflammation 2010, 7:31
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with 5% glucose or 500 nmol of Qa-2 siRNA or control
siRNA, and their PBMCs were analyzed one day and two
days later by flow cytometry. One day after Qa-2 siRNA
injection, the number of Qa-2 positive granulocytes was
32.18 ± 14.64%, which was significantly lower (p = 0.049)
than that of mice treated with 5% glucose (54.21 ± 1.89%)
or leader peptide (61.32 ± 12.27%) (Figure 3A). In lym-
phocytes, the Qa-2 positive cell counts did not differ sig-
nificantly among groups. Two days later, the frequency of
Qa-2 positive cells was 84.12 ± 10.34% in Qa-2 siRNA
injected mice, while it was 94.23 ± 3.86% of glucose
injected control mice in lymphocytes (p = 0.029). In gran-
ulocytes, the frequency of Qa-2 positive cells was 42.18 ±
28.40% in Qa-2 siRNA injected mice, while it was 75.65 ±
23.59% in glucose injected control mice (p = 0.008).
These findings demonstrated that Qa-2 siRNA effectively
reduced the frequencies of Qa-2 positive cells in lympho-
cytes and granulocytes in BD mice (Figure 3B). To deter-
mine if repeated administration can reduce the Qa-2 level
more efficiently, the frequency of Qa-2 positive cells in
BD mice that were injected with Qa-2 siRNA four times
was analyzed. To accomplish this, 500 nmol control
siRNA or Qa-2 siRNA in 200 μl of 5% glucose solution
was intraperitoneally injected four times with a three day
interval in between injections. Two days after the last
injection, the PBMCs were analyzed by FACS. In lympho-
cytes and granulocytes, Qa-2 siRNA led to a significant
reduction in Qa-2 positive cells when compared to glu-
Figure 3 Down-regulation of Qa-2 after intravenous injection of siRNA into BD mice. A. BD mice were injected once with control siRNA or Qa-
2 siRNA (500 nmol/mouse), which was composed of the α3 domain, transmembrane domain, and cytoplasmic domain. PBMC collected from the or-
bital sinus before and 1 day after injection were analyzed by flow cytometry. Qa-2 siRNA effectively reduced the Qa-2 levels in the PBMC of BD mice. 
B. Two days after injection, the frequency of Qa-2 positive lymphocytes and granulocytes was analyzed in Qa-2 siRNA injected BD mice. In lymphocytes 
and granulocytes, Qa-2 siRNA significantly reduced the number of Qa-2 positive cells when compared to glucose-injected control mice. C. The fre-
quency of Qa-2 positive cells in mice that were injected with Qa-2 siRNA four times. Specifically, 500 nmol control siRNA or Qa-2 siRNA in 200 μl of 5% 
glucose solution was intraperitoneally injected four times with a three day interval between injections, and the PBMC were analyzed by FACS two 
days after the last injection. In lymphocytes and granulocytes, Qa-2 siRNA significantly reduced the Qa-2 positive cells when compared to glucose 
injected control mice.
Table 2: Changes in symptoms after Qa-2 siRNA injection 
into BD mice
siRNA Deteriorated number/
total number
Qa-2 siRNA 3/6
Leader peptide siRNA 1/6
Glucose 0/7
The symptoms of BD mice deteriorated following treatment with 
Qa-2 siRNA. Qa-2 siRNA was intravenously injected into BD mice 
four times with a three day interval between injections. 
Deterioration occurred in three of six BD mice.Lee et al. Journal of Inflammation 2010, 7:31
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cose injected control mice (p = 0.05, p = 0.02 each) (Fig-
ure 3C). However, the reduction in Qa-2 level observed in
response to one and four injections did not differ signifi-
cantly.
The change in symptoms after Qa-2 siRNA injection into BD 
mice
To determine if down-regulation of Qa-2 could influence
the symptoms of BD, changes in symptoms (Table 2) and
the disease severity score were examined after adminis-
tration of siRNA to BD mice. Specifically, Qa-2 siRNA
was intravenously injected into BD mice four times with a
three day interval between treatments. After the injection
of siRNA, deterioration occurred in three of six BD mice
( F i g u r e  4 A ) .  H o w e v e r ,  i n  m i c e  t r e a t e d  w i t h  c o n t r o l
siRNA, the deterioration only occurred in one of the six
mice. In addition, there was no change in symptoms
observed in any of the seven BD mice injected with 5%
glucose. The change in symptoms was scored according
to the severity score of BD, which is outlined in the BD
Current Activity Form. As shown in Figure 4B, the score
of the Qa-2 siRNA-injected group increased from 5.66 ±
1.21 to 7.16 ± 2.04, although this change was not statisti-
cally significant (p = 0.07). In contrast, the score in the
control siRNA injected group increased to 4.0 ± 3.08
from 3.8 ± 2.68, while that of the glucose injected group
changed from 4.0 ± 1.41 to 3.4 ± 0.89.
Qa-2 siRNA increased IFNγ mRNA levels in spleens of BD 
mice
Recent in vitro studies have suggested that some duplex
siRNA sequences have non-specific effects and can
induce an IFN response, particularly at high concentra-
tions [29,30]. However, further studies are needed to
determine if these series of reactions can occur in vivo
and if this can occur in response to our siRNA sequences
[31]. Xie et al. reported that non-viral siRNA delivery to
diseased tissue does not elicit an immune response [32].
To determine the IFNγ mRNA expression, the spleen tis-
sues of BD mice that were injected with siRNA four times
were subjected to reverse transcriptase PCR (RT-PCR)
(Figure 5A) and real time PCR (Figure 5B). The IFNγ
mRNA expressions were increased in the Qa-2 siRNA-
injected mice when compared to the control siRNA or
glucose injected group. Increased IFNγ was not due to
siRNA, but rather to suppressed Qa-2 expression because
control siRNA did not increase the level of IFNγ. These
findings are in accordance with the finding that HLA-G-
expressing cells showed significantly reduced levels of
IFNγ [33].
Figure 4 Qa-2 siRNA deteriorated BD symptoms. For each mouse, 500 nmol each of control siRNA or Qa-2 siRNA in 200 ml of 5% glucose solution 
was intraperitoneally injected four times with three day intervals, and the symptoms were photographed (A) and the severity score was analyzed (B) 
two days after the last injection. The severity was lower in Qa-2 siRNA injected BD mice when compared to control siRNA injected BD mice, although 
this change was not significant. The disease score was estimated according to the Patients Index Score, Behcet's disease current activity form 2006, 
ICBD. The symptoms of BD mice deteriorated after treatment with Qa-2 siRNA. Deterioration occurred in three of six BD mice (A). When treated with 
control siRNA, the deterioration occurred in one of six mice, while no change was observed in any of the mice injected with 5% glucose.Lee et al. Journal of Inflammation 2010, 7:31
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Qa-2 expression vector decreased the frequency of IFNγ 
stained macrophages in BD mice
To confirm if Qa-2 could influence IFNγ expression, Qa-
2 vector was constructed in PC3.1 vector and then
administered to normal and BD mice. Cloning of the Qa-
2 gene of pGEM-Qa-2 into pcDNA3.1 vector was con-
firmed by digestion with EcoRI and BamHI (Figure 6A),
after which the inserted sequence was confirmed by
sequencing using T7 promoter (Figure 6B). The vector
was intraperitoneally injected once into mice, and perito-
neal macrophages and splenocytes were isolated four
days later. As shown in Figure 7, the frequency of Qa-2
expressing cells in splenocytes increased to 94.53 ± 0.64%
in the Qa-2 vector injected mice, while it was 89.83 ±
2.66% in control vector injected mice (p = 0.45). Addi-
tionally, their frequency in macrophages increased to
82.25 ± 5.62% in the Qa-2 vector injected mice, while it
was 67.53 ± 4.66% in control vector injected mice (p =
0.003). The IFNγ levels in macrophages of Qa-2 vector-
injected mice also decreased to 16.60 ± 6.11%, while they
were 66.24 ± 7.28% in control mice (p < 0.001) (Figure 8).
Qa-2 expression vector appeared to work in mac-
rophages, and these effects were accompanied by a
decrease in IFNγ.
The frequency of NK cells in BD and BDN mice
To confirm the relationship between HLA-G and the NK
cells, the frequency of NK cells was observed in BD and
BDN mice using flow cytometry. As shown in Figure 9,
the frequency of NK cells in splenocytes was 13.8 ± 2.2%
in BD mice (n = 9) when compared to BDN mice (5.4 ±
0.3%) (n = 5, p < 0.001) and normal mice (8.9 ± 1.1%) (n =
7, p < 0.001). The frequency of NK cells in BD mice was
higher than BDN. These findings indicate that down-reg-
ulation of HLA-G may influence the higher frequency of
NK cells in BD mice.
Figure 5 The expression of IFN-γ mRNA in the spleens of glucose, 
control siRNA, and Qa-2 siRNA-injected BD mice. The expression of 
IFN-γ mRNA as shown by RT-PCR (A) and real time PCR (B). IFNγ mRNA 
expression was increased in the Qa-2 siRNA-injected mice.
Figure 6 Construction of a Qa-2 expression vector. A. pcDNA3.1-Qa-2 was constructed by insertion of the full length mouse Qa-2 gene into the 
EcoR1 and BamH1 restriction site (expected size: 1.36 kb + 5.43 kb). The inserted Qa-2 gene was confirmed by digestion with EcoRI and BamHI. B. Vec-
tor inserted Qa-2 was sequenced using T7 promoter.Lee et al. Journal of Inflammation 2010, 7:31
http://www.journal-inflammation.com/content/7/1/31
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Discussion
In this study, Qa-2 expression in HSV-induced BD mice
was investigated and compared to that of normal mice
and BD asymptomatic mice. The number of Qa-2 positive
granulocytes in PBMC was lower in BD mice than in BD
asymptomatic or normal healthy mice. Among BD mice,
the Qa-2 frequency of PBMC in BD eye mice was lower
than in BD skin mice, and the differences were larger in
granulocytes than lymphocytes. mRNA expression also
showed a pattern similar to the FACS frequency. Further-
more, we found that the in vivo injection of Qa-2 siRNA
reduced the Qa-2 mRNA and protein levels in PBMC of
BD mice and deteriorated BD symptoms. Taken together,
these findings indicate that down-regulation of Qa-2
could be an important factor in worsening of BD symp-
toms.
It has been reported that genetic variants with a 14-bp
deletion polymorphism in the HLA-G region are associ-
ated with Kawasaki disease [34], juvenile idiopathic
arthritis [35], ulcerative colitis, and Crohn's disease [36].
In patients with Behcet's disease, the frequency of haplo-
types containing the HLA-G 3741_3754  14 base pair
insertion and 1597*delC was found to increase, and this
insertion was associated with a lower serum level of
HLA-G [26]. In the present study, we found that Qa-2
mRNA and Qa-2 positive PBMCs were significantly
lower in BD symptomatic mice than in normal healthy
mice.
RNA interference has emerged as a powerful tool to
inhibit protein expression [37], and we previously
reported that TNF alpha siRNA and IL-6 siRNA inhibited
the serum protein level of TNF alpha and IL-6 in vivo in
the BD mouse model [38,39]. In the present study, Qa-2
siRNA was found to reduce Qa-2 mRNA levels and pro-
tein expression in vitro in PBMCs isolated from normal
mice, and intravenous injection of siRNA into BD mice
down-regulated the frequency of Qa-2 expression in lym-
phocytes and granulocytes of BD mice. Treatment of BD
mice with Qa-2 siRNA resulted in deterioration of symp-
toms such as skin ulcer and arthritis, and decreased Qa-2
Figure 7 Expression of pc3.1DNA Qa-2 vector in vivo in normal mice. The frequency of Qa-2 protein in splenocytes and macrophages isolated 
from normal mice injected with 50 μg pc3.1DNA Qa-2 vector as determined by FACS analysis. The macrophages isolated from mice injected with 
pc3.1DNA Qa-2 vector showed a higher frequency of Qa-2 positive cells when compared to the non-injected control (p = 0.01) and pc3.1 DNA vector-
injected mice (p = 0.003). The splenocytes also showed a higher frequency of Qa-2 positive cells when compared to the non-injected control and 
pc3.1 DNA vector injected mice, although this difference was not significant.Lee et al. Journal of Inflammation 2010, 7:31
http://www.journal-inflammation.com/content/7/1/31
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levels were found to be related to changes in the disease
progression. Control siRNA injection to BD mice did not
change the BD symptoms and disease severity score. The
inhibitory function of HLA-G might be important in reg-
ulation of the immune responses [40].
HLA-G also influences the Th cytokine balance toward
Th2 by promoting the secretion of IL-3, IL-4 and IL-10
while down-regulating the production of IFNγ and TNFα
[41-43]. In the present study, Qa-2 siRNA increased the
IFNγ mRNA levels in the spleens of BD mice, whereas
control siRNA did not increase the IFNγ mRNA levels.
The increase in IFNγ mRNA levels after injection of Qa-2
siRNA to BD mice was not due to a non-specific immune
response, but rather to down-regulation of Qa-2. In addi-
tion, the present results showed that the injection of Qa-2
expression vector decreased IFNγ-stained macrophages
in BD mice.
It has been suggested that genetic, immunologic and
inflammatory factors play a significant role in susceptibil-
ity to BD [44]. NK cells play a role in induction and/or
regulation of various types of immune responses, includ-
ing several autoimmune diseases, through cytotoxicity
and cytokine production [45]. Several studies have shown
natural killer (NK)-mediated cytotoxicity, and cytokine
secretion is believed to play roles in the immunopatho-
genesis of Behcet's disease [46,47]. Functionally, HLA-G
directly inhibits the cytolytic function of peripheral blood
NK cells [48]. The frequency of NK cells was found to be
higher in BD mice than BDN mice. Increased numbers of
NK cells have been reported in patients with BD [49]. The
down-regulation of Qa-2 by siRNA might increase the
number of NK cells, and the increase of NK cells might
play an important role in the pathogenesis of BD.
Conclusions
Qa-2 levels were lower in the PBMC of BD mice than in
the PBMC of normal mice. In addition, Qa-2 levels were
lower in BD mice with eye involvement than in BD mice
with mucocutaneous involvement and BD asymptomatic
mice. Qa-2 siRNA effectively reduced Qa-2 mRNA
expression in PBMC culture and the frequency of Qa-2
positive PBMC in BD mice, indicating that Qa-2 siRNA
effectively reduced Qa-2 expression both in vitro and in
vivo. Qa-2 siRNA was capable of modulating BD-like
symptoms, leading to deterioration of BD mice. The
results of this study confirmed that decreased Qa-2 levels
are related to changes in the disease pattern and deterio-
ration of BD-like symptoms.
Figure 8 Expression of Qa-2 and IFNγ in the macrophages of Qa-2 vector injected BD mice as shown by FACS analysis. BD mice were intrap-
eritoneally injected once with 50 μg of pcDNA 3.1 vector or pcDNA 3.1 Qa-2 vector and their macrophages were analyzed four days later by flow cy-
tometry. Qa-2 positive cells were increased in the Qa-2 vector injected mice, whereas IFNγ positive cells decreased.
Figure 9 The frequency of NK cells in BD and BDN mice. The fre-
quency of NK cells was analyzed in BD and BDN mice using flow cy-
tometry.Lee et al. Journal of Inflammation 2010, 7:31
http://www.journal-inflammation.com/content/7/1/31
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